西北药学杂志
西北藥學雜誌
서북약학잡지
Northwest Pharmaceutical Journal
2015年
6期
737-739
,共3页
孟鲁司特钠%妥洛特罗贴剂%儿童咳嗽变异性哮喘
孟魯司特鈉%妥洛特囉貼劑%兒童咳嗽變異性哮喘
맹로사특납%타락특라첩제%인동해수변이성효천
montelukast%tulobuterol patch%children with cough variant asthma
目的:探讨孟鲁司特钠联合妥洛特罗贴剂在儿童咳嗽变异性哮喘(CVA)治疗中的价值。方法将医院2012年1月~2014年1月收治的116例CVA患儿随机分为2组,对照组采用孟鲁司特钠治疗,观察组采用孟鲁司特钠联合妥洛特罗贴剂治疗,比较2组患儿肺功能改善情况、咳嗽缓解和消失时间、治疗总有效率,并比较2组治疗前后血清白细胞介素‐4(IL‐4)、γ干扰素(IFN‐γ)水平变化情况。结果治疗前2组FVC、FEV1、PEF差异无统计学意义;治疗后2组上述指标均增加,且观察组各项指标均高于对照组,差异均有统计学意义(P<0.05);观察组咳嗽缓解、消失时间短于对照组(P<0.05),观察组总有效率高于对照组(X2=5.583,P=0.018),差异有统计学意义。治疗前2组患儿血清IL‐4、IFN‐γ水平差异无统计学意义,治疗后2组血清IL‐4降低,观察组低于对照组,IFN‐γ水平升高,观察组高于对照组( P<0.05)。结论孟鲁司特钠联合妥洛特罗贴剂治疗儿童CVA可有效改善肺功能、缓解咳嗽症状,提高临床疗效。
目的:探討孟魯司特鈉聯閤妥洛特囉貼劑在兒童咳嗽變異性哮喘(CVA)治療中的價值。方法將醫院2012年1月~2014年1月收治的116例CVA患兒隨機分為2組,對照組採用孟魯司特鈉治療,觀察組採用孟魯司特鈉聯閤妥洛特囉貼劑治療,比較2組患兒肺功能改善情況、咳嗽緩解和消失時間、治療總有效率,併比較2組治療前後血清白細胞介素‐4(IL‐4)、γ榦擾素(IFN‐γ)水平變化情況。結果治療前2組FVC、FEV1、PEF差異無統計學意義;治療後2組上述指標均增加,且觀察組各項指標均高于對照組,差異均有統計學意義(P<0.05);觀察組咳嗽緩解、消失時間短于對照組(P<0.05),觀察組總有效率高于對照組(X2=5.583,P=0.018),差異有統計學意義。治療前2組患兒血清IL‐4、IFN‐γ水平差異無統計學意義,治療後2組血清IL‐4降低,觀察組低于對照組,IFN‐γ水平升高,觀察組高于對照組( P<0.05)。結論孟魯司特鈉聯閤妥洛特囉貼劑治療兒童CVA可有效改善肺功能、緩解咳嗽癥狀,提高臨床療效。
목적:탐토맹로사특납연합타락특라첩제재인동해수변이성효천(CVA)치료중적개치。방법장의원2012년1월~2014년1월수치적116례CVA환인수궤분위2조,대조조채용맹로사특납치료,관찰조채용맹로사특납연합타락특라첩제치료,비교2조환인폐공능개선정황、해수완해화소실시간、치료총유효솔,병비교2조치료전후혈청백세포개소‐4(IL‐4)、γ간우소(IFN‐γ)수평변화정황。결과치료전2조FVC、FEV1、PEF차이무통계학의의;치료후2조상술지표균증가,차관찰조각항지표균고우대조조,차이균유통계학의의(P<0.05);관찰조해수완해、소실시간단우대조조(P<0.05),관찰조총유효솔고우대조조(X2=5.583,P=0.018),차이유통계학의의。치료전2조환인혈청IL‐4、IFN‐γ수평차이무통계학의의,치료후2조혈청IL‐4강저,관찰조저우대조조,IFN‐γ수평승고,관찰조고우대조조( P<0.05)。결론맹로사특납연합타락특라첩제치료인동CVA가유효개선폐공능、완해해수증상,제고림상료효。
Objective To investigate the effect of montelukast combined with tulobuterol patch on cough variant asthma (CVA) in children .Methods 116 children patients with CVA admitted to the Xili People′s Hospital in Nanshan District from January ,2012 to January ,2014 were randomly divided into two groups ,with 58 cases in each group .The control group were treated with monte‐lukast ,while the observation group were treated with montelukast combined with tulobuterol patch .The improvement condition of pulmonary function ,cough relieving and disappearing time ,the total efficiency of the treatment of children in two groups were compared .The serum leukocyte mediated‐4 (IL‐4) ,interferon gamma (IFN‐gamma) changes before and after the treatment were measured .Results There was no statistically significant difference in FVC ,FEV1 ,PEF before the treatment ,while the indexes a‐bove mentioned increased after the treatment .The indicators of the observation group were higher than that of the control group (P< 0 .05) .The symptom remission time and disappearance of cough of the observation group were shorter than those of the con‐trol group ,and there was statistically significant difference (P< 0 .05) .The total effective rate of the observation group was high‐er than that of the control group (X2 =5 .583 ,P=0 .018) ,and the difference was statistically significant .There was no statistical‐ly significant difference in serum IL‐4 ,IFN‐levels before the treatment between the two groups ,while serum IL‐4 decreased after the treat‐ment .The observation group was lower than that of the control group ,IFN‐levels increased .The observation group was higher than that of the control group(P< 0 .05) .Conclusion Montelukast combined with tulobuterol patch on CVA in children can ef‐fectively improve the lung function ,relieve cough symptoms ,and improve the clinical curative effect .